• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Surgical Oncology >A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy.
【24h】

A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy.

机译：肝动脉输注泵化疗对无法切除的转移性结直肠癌进行射频消融的II期研究。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Adjuvant hepatic arterial infusion (HAI) chemotherapy has been demonstrated to improve disease-free survival for colorectal cancer liver metastases. It is unclear if this improvement can be extrapolated to unresectable liver metastases that undergo RFA. The aim of this study was to evaluate the combination of RFA and HAI chemotherapy for unresectable liver metastases. METHODS: Phase II study was conducted from November 2000 to July 2003 evaluating the use of complete extirpation by RFA, or resection/ablation with adjuvant HAI consisting of FUDR for 6 months. RESULTS: Twenty-one patients had successful resection and/or RFA with HAI pump, which included treatment for 100 liver metastases (22 resected, 78 ablated; mean 4.8 tumors/patient). Four of 21 patients completed the full 6-month course of HAI. Six of these patients had 12 adverse events related to HAIP, most commonly elevated liver enzymes. After a median follow-up of 24 months, the median liver specific disease-free and overall survival rates for the entire group were 17 and 30 months, respectively. CONCLUSIONS: Given the complications and toxicity associated with HAI pump chemotherapy, adjuvant HAI chemotherapy after RFA of liver metastases may not be warranted as a first line treatment option.
机译：背景：辅助肝动脉输注（HAI）化疗已被证明可改善大肠癌肝转移的无病生存期。目前尚不清楚这种改善是否可以推断为接受RFA的不可切除的肝转移。本研究的目的是评估RFA和HAI化疗联合治疗无法切除的肝转移的可能性。方法：第二阶段研究于2000年11月至2003年7月进行，评估使用RFA完全根除术，或用FUDR组成的HAI辅助切除/切除术治疗6个月。结果：21例患者使用HAI泵成功切除和/或RFA，其中包括100例肝转移的治疗（22例切除，78例消融;平均4.8例/患者）。 21名患者中有4名完成了HAI整个6个月的疗程。这些患者中有6名发生了12种与HAIP相关的不良事件，最常见的是肝酶升高。中位随访24个月后，整个组的中位无肝特异性疾病和总生存率分别为17个月和30个月。结论：考虑到与HAI泵化疗相关的并发症和毒性，RFA肝转移术后辅助HAI化疗可能不作为一线治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号